Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:CBDC - Apotheca Biosciences Stock Price, Forecast & News

$0.01
+0.01 (+9,900.00 %)
(As of 01/22/2020 08:00 AM ET)
Today's Range
$0.01
Now: $0.01
$0.02
50-Day Range
$0.00
MA: $0.01
$0.03
52-Week Range
$0.00
Now: $0.01
$0.40
Volume4,072 shs
Average Volume5,563 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulation, and delivery technologies for the healthcare and consumer care industry. The company is based in the United States.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBDC
CUSIPN/A
CIKN/A
WebN/A
Phone727-228-3994

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CBDC News and Ratings via Email

Sign-up to receive the latest news and ratings for CBDC and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

This little-known smart chip is crucial for the new 5G networks. And with 1 billion 5G devices coming online within 4 years...the market is estimated to be worth $12.3 TRILLION! This just-released special report reveals urgent details.

Apotheca Biosciences (NASDAQ:CBDC) Frequently Asked Questions

What is Apotheca Biosciences' stock symbol?

Apotheca Biosciences trades on the NASDAQ under the ticker symbol "CBDC."

Has Apotheca Biosciences been receiving favorable news coverage?

Press coverage about CBDC stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apotheca Biosciences earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Apotheca Biosciences.

Who are some of Apotheca Biosciences' key competitors?

What other stocks do shareholders of Apotheca Biosciences own?

Who are Apotheca Biosciences' key executives?

Apotheca Biosciences' management team includes the folowing people:
  • Dr. P. C. Sundareswaran, Chairman, CEO & CFO
  • Ms. Deirdre Fernandes, COO & Director
  • Mr. John Verghese, CTO & Director (Age 58)
  • Mr. Craig Huffman, Legal Council
  • Karin Rohret, Sec.

How do I buy shares of Apotheca Biosciences?

Shares of CBDC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Apotheca Biosciences' stock price today?

One share of CBDC stock can currently be purchased for approximately $0.01.

How can I contact Apotheca Biosciences?

The company can be reached via phone at 727-228-3994.


MarketBeat Community Rating for Apotheca Biosciences (NASDAQ CBDC)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  56
MarketBeat's community ratings are surveys of what our community members think about Apotheca Biosciences and other stocks. Vote "Outperform" if you believe CBDC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBDC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel